NASDAQ:PALI Palisade Bio Q3 2026 Earnings Results & Report $1.13 -0.06 (-5.04%) Closing price 04:00 PM EasternExtended Trading$1.16 +0.03 (+2.21%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Palisade Bio missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.07 versus the -$0.06 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call7:00 AM ET Palisade Bio EPS ResultsActual EPS-$0.07Consensus EPS -$0.06Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersPalisade Bio Revenue ResultsActual RevenueN/AExpected Revenue$465 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Palisade Bio Q3 2026 Earnings FAQ Did Palisade Bio beat earnings estimates for Q3 2026? Palisade Bio (NASDAQ:PALI) reported earnings of -$0.07 per share for Q3 2026, missing the consensus estimate of -$0.06. The report was announced on Tuesday, November 10, 2026. Palisade Bio Earnings HeadlinesPalisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 202648 minutes ago | marketscreener.comMPalisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development ProgramsNovember 10 at 4:25 PM | globenewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Palisade Bio (PALI) Projected to Announce Quarterly Earnings on MondayNovember 8 at 2:10 AM | americanbankingnews.comPalisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 InhibitorNovember 2, 2026 | seekingalpha.comPalisade Doses First Patient In Phase 2b Ulcerative Colitis Trial; Data Expected Q4 2027October 29, 2026 | rttnews.comSee More Palisade Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email. Email Address About Palisade BioPalisade Bio (NASDAQ:PALI) (NASDAQ: PALI) is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and complications associated with gastrointestinal surgery. The company’s research is centered on treatments intended to protect the intestinal barrier and support recovery following major medical procedures. Palisade Bio’s lead product candidate, LB1148, is an orally administered serine protease inhibitor designed to reduce the harmful effects of digestive enzymes released during surgery or gastrointestinal injury. The company has investigated LB1148 in clinical studies involving postoperative recovery, including complications such as delayed return of bowel function and postoperative ileus. Palisade Bio has also evaluated potential applications for the compound in other gastrointestinal conditions. The company is based in Carlsbad, California, and advances its programs through clinical development and partnerships with research institutions and healthcare organizations. As a development-stage biotechnology company, Palisade Bio’s products remain subject to clinical testing and regulatory review before they can be broadly marketed.View Palisade Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
